With Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) in the crosshairs, Kodiak Sciences Inc. let Wall Street know that ...
Sofinnova Partners reported the final close of its fourth early stage med-tech fund at €82 million (US$93.5 million). The ...
Abbvie Inc.’s selective D1/D5 receptor agonist, Juvmo (tavapadon), a first-in-class dopamine D1/D4 selective partial agonist ...
It was a double dose of good news for Mirum Pharmaceuticals Inc., which late Friday, Sept. 25, reported U.S. FDA approval of ...
Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. voluntarily withdrew their BLA for ifinatamab deruxtecan (i-dxd), a ...
Taking on a preclinical oral KRAS G12D (on) inhibitor, Merck & Co. Inc. entered an exclusive global license oncology deal ...
As she reaches the end of a six-year mandate, Emer Cooke, executive director of the EMA, said she continues to be shocked at ...
Ateam of researchers from the University of Toronto and Oxford Population Health have shed some light on the interpretation ...
Thalia Therapeutics plc has completed initial chemistry synthesis of siRNA gene-silencing medicines for its cardiovascular program, THAT-002. THAT-002 is being developed as a potentially long-duration ...
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare autosomal-recessive cholestatic liver disease caused ...
Co. Ltd. has obtained IND clearance from the FDA for NTS-231, a covalent allosteric molecular glue degrader of NRF2.
Sola Biosciences Japan GK, the wholly owned Japanese subsidiary of Sola Biosciences Inc., has been awarded a grant of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results